1. Articles in category: Immune Therapy

    1-24 of 366 1 2 3 4 ... 14 15 16 »
    1. Sequential actions of immune effector cells induced by viral activation of dendritic cells to eliminate murine neuroblastoma.

      Sequential actions of immune effector cells induced by viral activation of dendritic cells to eliminate murine neuroblastoma.

      J Pediatr Surg. 2017 Aug 26;:

      Authors: Kawakubo N, Tanaka S, Kinoshita Y, Tajiri T, Yonemitsu Y, Taguchi T

      Abstract PURPOSE: In preclinical trails, we reported the antitumor effect of dendritic cells activated with Sendai virus (rSeV/DC) combined with γ-irradiation against neuroblastoma.

      Read Full Article
    2. GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

      GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

      Cancer Discov. 2017 Sep 22;:

      Authors:

      Abstract A GPC2-targeting antibody-drug conjugate promotes tumor regression in a high-risk neuroblastoma PDX.

      PMID: 28939655 [PubMed - as supplied by publisher]

      Read Full Article
      Mentions: Antibody
    3. A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma.

      A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma.

      Clin Cancer Res. 2017 Sep 22;:

      Authors: Federico SM, McCarville MB, Shulkin BL, Sondel PM, Hank JA, Hutson P, Meagher M, Shafer A, Ng CY, Leung W, Janssen WE, Wu J, Mao S, Brennan RC, Santana VM, Pappo A, Furman WL

      Read Full Article
    4. When good immune cells turn bad

      When good immune cells turn bad

      Investigators at the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles have identified new findings about an immune cell - called a tumor-associated macrophage - that promotes cancer instead of fighting it. They have identified the molecular pathway, known as STAT3, as the mechanism the immune cell uses to foster neuroblastoma, a pediatric cancer, and have demonstrated use of a clinically available agent, ruxolitinib, to block the pathway.

      Read Full Article
    5. Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma.

      Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma.

      Cancer Cell. 2017 Sep 11;32(3):271-273

      Authors: Malone CF, Stegmaier K

      Abstract In this issue of Cancer Cell, Bosse et al. report GPC2 as a therapeutic target in neuroblastoma. They show that GPC2 is selectively expressed on the cell surface of neuroblastoma and is a dependency in this disease. Moreover, they demonstrate the therapeutic potential of an antibody-drug conjugate targeting GPC2.

      Read Full Article
      Mentions: Antibody
    6. Cell surface protein may offer big target in treating high-risk childhood cancers

      Cell surface protein may offer big target in treating high-risk childhood cancers

      Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy--harnessing the immune system in medical treatments.

      In cell cultures and animal models, a potent drug attached to an...

      Read Full Article
      Mentions: Immunotherapy
    7. Modulating T-cell metabolism uncovers new technology for enhancing immunotherapy

      Modulating T-cell metabolism uncovers new technology for enhancing immunotherapy

      T lymphocytes found in tumors and implicated in killing tumor cells cope with the shortage of oxygen and nutrients in the tumor microenvironment by using fat as the main source of energy. Promoting a switch from glucose to fatty acid to generate energy enhances T cell antitumor activity. These findings from a study conducted at The Wistar Institute were published in the journal Cancer Cell.

      Read Full Article
    8. Cell surface protein may offer big target in treating high-risk childhood cancers

      Cell surface protein may offer big target in treating high-risk childhood cancers

      ( Children's Hospital of Philadelphia ) Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy -- harnessing the immune system in medical treatments. In cell cultures and animal models, a potent drug attached to an antibody selectively zeroes in on cancer cells without harming healthy cells.

      Read Full Article
    9. Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma.

      Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Aug 14;:

      Authors: Glincher R, Price AP, LaQuaglia MP, Kushner BH, Modak S

      Abstract The antivascular endothelial growth factor antibody, bevacizumab, is effective against several malignancies in adults but unproven in pediatric oncology. In early phase pediatric studies toxicities were similar to those in adults.

      Read Full Article
      Mentions: Antibody
    10. CHLA Researcher Awarded $1.9 Million by NIH to Study Novel Approach to Battling Neuroblastoma

      CHLA Researcher Awarded $1.9 Million by NIH to Study Novel Approach to Battling Neuroblastoma

      Muller Fabbri, MD, PhD, of the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles, has been awarded $1.9 million by the National Cancer Institute of the NIH to further his research on neuroblastoma.

      Read Full Article
    11. Anti-GD2 immunotherapy for neuroblastomas.

      Anti-GD2 immunotherapy for neuroblastomas.

      Expert Rev Anticancer Ther. 2017 Aug 07;:

      Authors: Sait S, Modak SI

      Abstract INTRODUCTION: Current therapeutic approaches for high-risk neuroblastoma (HR-NB) include high-dose chemotherapy, surgery and radiotherapy; interventions that are associated with long and short-term toxicities. Effective immunotherapy holds particular promise for improving survival and quality of life by reducing exposure to cytotoxic agents.

      Read Full Article
    12. Seattle Children's Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia Escapes CD19 CAR T-Cell Therapy

      Seattle Children's Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia Escapes CD19 CAR T-Cell Therapy

      After seeing promising results in phase 1 of the Pediatric Leukemia Adoptive Therapy (PLAT-02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 percent.

      Read Full Article
    13. Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series

      Immunotherapy with the anti-GD2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population. To date, transverse myelitis as a result of dinutuximab therapy has not been reported in clinical trials or in the published literature.

      Read Full Article
    14. Seattle Children's opens CD22 CAR T-cell immunotherapy trial for children and young adults

      Seattle Children's opens CD22 CAR T-cell immunotherapy trial for children and young adults

      ( Seattle Children's ) After seeing promising results in phase 1 of the Pediatric Leukemia Adoptive Therapy (PLAT-02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 percent.

      Read Full Article
    15. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.

      Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.

      Proc Natl Acad Sci U S A. 2017 Jul 24;:

      Authors: Li N, Fu H, Hewitt SM, Dimitrov DS, Ho M

      Abstract Neuroblastoma is a childhood cancer that is fatal in almost half of patients despite intense multimodality treatment. This cancer is derived from neuroendocrine tissue located in the sympathetic nervous system.

      Read Full Article
      Mentions: Antibody Treatment
    16. Consolidation Therapy for Newly Diagnosed Pediatric High-Risk Neuroblastoma Patients Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplant, Anti-GD2 Antibody, GM-CSF, IL-2 and Haploidentical NK Cells.

      Consolidation Therapy for Newly Diagnosed Pediatric High-Risk Neuroblastoma Patients Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplant, Anti-GD2 Antibody, GM-CSF, IL-2 and Haploidentical NK Cells.

      Biol Blood Marrow Transplant. 2017 Jul 18;:

      Authors: Talleur AC, Triplett BM, Federico S, Mamcarz E, Janssen W, Wu J, Shook D, Leung W, Furman WL

      Read Full Article
      Mentions: Antibody NK Cells
    17. γδTFH cells promote B cell maturation and antibody production in neuroblastoma.

      γδTFH cells promote B cell maturation and antibody production in neuroblastoma.

      BMC Immunol. 2017 Jul 07;18(1):36

      Authors: Mou W, Han W, Ma X, Wang X, Qin H, Zhao W, Ren X, Chen X, Yang W, Cheng H, Wang X, Zhang H, Ni X, Wang H, Gui J

      Abstract BACKGROUND: Previous studies have shown that γδ TFH cells are capable of modulating antibody production in immunized and infected mouse model.

      Read Full Article
      Mentions: Antibody
    18. Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.

      Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.

      Oncoimmunology. 2017;6(6):e1320625

      Authors: Hoseini SS, Dobrenkov K, Pankov D, Xu XL, Cheung NV

      Abstract Chimeric antigen receptors (CAR) and bispecific antibodies (BsAb) are two powerful immunotherapy approaches for retargeting lymphocytes toward cancer cells. Despite their success in lymphoblastic leukemia, solid tumors have been more recalcitrant.

      Read Full Article
    19. MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.

      MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.

      Oncoimmunology. 2017;6(6):e1316439

      Authors: Brandetti E, Veneziani I, Melaiu O, Pezzolo A, Castellano A, Boldrini R, Ferretti E, Fruci D, Moretta L, Pistoia V, Locatelli F, Cifaldi L

      Read Full Article
      Mentions: MYCN
    20. Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression.

      Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression.

      Oncoimmunology. 2017;6(6):e1320626

      Authors: Layer JP, Kronmüller MT, Quast T, van den Boorn-Konijnenberg D, Effern M, Hinze D, Althoff K, Schramm A, Westermann F, Peifer M, Hartmann G, Tüting T, Kolanus W, Fischer M, Schulte J, Hölzel M

      Read Full Article
      Mentions: MYCN
    21. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.

      Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.

      Mol Ther. 2017 Jul 01;:

      Authors: Walker AJ, Majzner RG, Zhang L, Wanhainen K, Long AH, Nguyen SM, Lopomo P, Vigny M, Fry TJ, Orentas RJ, Mackall CL

      Read Full Article
      Mentions: ALK
    22. Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.

      Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.

      Tumour Biol. 2017 Jul;39(7):1010428317701309

      Authors: Krishnadas DK, Wang Y, Sundaram K, Bai F, Lucas KG

      Abstract The cancer germline antigens MAGE-A1, MAGE-A3, and NY-ESO-1 can be used to target relapsed or therapy-resistant malignant solid tumors, and previous studies have demonstrated that these antigens can be epigenetically upregulated on the surface of tumor cells following exposure to low-dose demethylating chemotherapy agents, such as decitabine. The extent to which cancer germline antigen cytotoxic T lymphocytes can be reliably expanded from healthy donors has not been well characterized, specifically in ...

      Read Full Article
    23. Treatment of Transient Peripheral Neuropathy During Chimeric 14.18 Antibody Therapy in Children With Neuroblastoma: A Case Series.

      Treatment of Transient Peripheral Neuropathy During Chimeric 14.18 Antibody Therapy in Children With Neuroblastoma: A Case Series.

      J Pediatr Hematol Oncol. 2017 Jul 03;:

      Authors: Ari P, Kars M, Meany H, Pestieau S

      Abstract Children with high-risk neuroblastoma are currently treated with a chimeric monoclonal antibody against GD2 ganglioside (chimeric 14.18). The treatment improves survival but causes transient neuropathic pain-like syndrome.

      Read Full Article
      Mentions: Antibody Treatment
    1-24 of 366 1 2 3 4 ... 14 15 16 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (5 articles) Antibody
    2. (3 articles) Immunotherapy
    3. (1 articles) Vaccine
  4. Treatments in the News

    1. (1 articles) Refractory
    2. (1 articles) Chemotherapy